View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika Budapest
  • 2 Richter Gedeon NyRt. Budapest
  • 3 Magyar Tudományos Akadémia–Semmelweis Egyetem Molekuláris Medicina Kutatócsoport Budapest Szentkirályi u. 46. 1088
  • 4 Semmelweis Egyetem Laboratóriumi Medicina Intézet Budapest

A glükokortikoidok szabályozzák a szénhidrát- és aminosav-anyagcserét, modulálják az immunrendszer működését és a stresszre adott válaszreakciókat. Elégtelen, illetve fokozott szekréciójuk jellegzetes kórképeket okoz. A szervezet glükokortikoidhormon-ellátottsága mellett az utóbbi évtizedben előtérbe került az adott szövetekben lokálisan képződő glükokortikoidok patofiziológiai szerepének kutatása. A lokális glükokortikoidellátottság egyik kulcsenzime a sejtek endoplazmatikus reticulumában elhelyezkedő 11-β-hidroxi-szteroid-dehidrogenáz enzim 1-es és 2-es típusa, amelyek az inaktív kortizon és az aktív kortizol közötti kétirányú átalakulást katalizálják. Az 1-es típusú enzim elsősorban a kortizon aktiválásában játszik szerepet és főként a májban, gonádokban, zsírszövetben, agyban és csontban a biológiailag aktív kortizol lokális képződéséért felelős. Az enzimet kódoló gén az 1-es kromoszómán található. A szerzők jelen munkájukban összefoglalják a 11-β-hidroxi-szteroid-dehidrogenáz enzim 1-es típusának működésével kapcsolatba hozható klinikai és (kór)élettani folyamatokat. Összefoglalójukban áttekintik az enzimaktivitás gátlásában szerepet játszó genetikai variánsokkal kapcsolatos legfontosabb ismereteket és az enzimaktivitást gátló vegyületekkel szerzett tapasztalatokat. Az eredmények összegzéséből kitűnik, hogy bár ismereteink sok területen még hiányosak, az 1-es típusú enzim működésének és/vagy termelődésének gyógyszeres befolyásolása ígéretes terápiás lehetőséget jelenthet elhízásban, csontritkulásban vagy akár cukorbetegségben szenvedő betegek kezelésében. Orv. Hetil., 2013, 154, 283–293.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • Tomlinson, J. W., Walker, E. A., Bujalska, I. J., et al.: 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocr. Rev., 2004, 25, 831–866.

    Bujalska I. J. , '11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response ' (2004 ) 25 Endocr. Rev. : 831 -866.

    • Search Google Scholar
  • Miguet, L., Zhang, Z., Barbier, M., et al.: Comparison of a homology model and the crystallographic structure of human 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) in a structure-based identification of inhibitors. J. Comput. Aided Mol. Des., 2006, 20, 67–81.

    Barbier M. , 'Comparison of a homology model and the crystallographic structure of human 11beta-hydroxysteroid dehydrogenase type 1 (11betaHSD1) in a structure-based identification of inhibitors ' (2006 ) 20 J. Comput. Aided Mol. Des. : 67 -81.

    • Search Google Scholar
  • Makkonen, J., Westerbacka, J., Kolak, M., et al.: Increased expression of the macrophage markers and of 11beta-HSD-1 in subcutaneous adipose tissue, but not in cultured monocyte-derived macrophages, is associated with liver fat in human obesity. Int. J. Obes. (Lond.), 2007, 31, 1617–1625.

    Kolak M. , 'Increased expression of the macrophage markers and of 11beta-HSD-1 in subcutaneous adipose tissue, but not in cultured monocyte-derived macrophages, is associated with liver fat in human obesity ' (2007 ) 31 Int. J. Obes. (Lond.) : 1617 -1625.

    • Search Google Scholar
  • Ahmed, A., Saksena, S., Sherlock, M., et al.: Induction of hepatic 11beta-hydroxysteroid dehydrogenase type 1 in patients with alcoholic liver disease. Clin. Endocrinol. (Oxf.), 2008, 68, 898–903.

    Sherlock M. , 'Induction of hepatic 11beta-hydroxysteroid dehydrogenase type 1 in patients with alcoholic liver disease ' (2008 ) 68 Clin. Endocrinol. (Oxf.) : 898 -903.

    • Search Google Scholar
  • Huang, Y., Li, X., Lin, H., et al.: Regulation of 11beta-hydroxysteroid dehydrogenase 1 and 2 by IGF-1 in mice. Biochem. Biophys. Res. Commun., 2010, 391, 1752–1756.

    Lin H. , 'Regulation of 11beta-hydroxysteroid dehydrogenase 1 and 2 by IGF-1 in mice ' (2010 ) 391 Biochem. Biophys. Res. Commun. : 1752 -1756.

    • Search Google Scholar
  • Morton, N. M., Seckl, J. R.: 11beta-hydroxysteroid dehydrogenase type 1 and obesity. Front. Horm. Res., 2008, 36, 146–164.

    Seckl J. R. , '11beta-hydroxysteroid dehydrogenase type 1 and obesity ' (2008 ) 36 Front. Horm. Res. : 146 -164.

    • Search Google Scholar
  • Seckl, J. R., Morton, N. M., Chapman, K. E., et al.: Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue. Rec. Prog. Horm. Res., 2004, 59, 359–393.

    Chapman K. E. , 'Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue ' (2004 ) 59 Rec. Prog. Horm. Res. : 359 -393.

    • Search Google Scholar
  • Marcolongo, P., Senesi, S., Gava, B., et al.: Metyrapone prevents cortisone-induced preadipocyte differentiation by depleting luminal NADPH of the endoplasmic reticulum. Biochem. Pharmacol., 2008, 76, 382–390.

    Gava B. , 'Metyrapone prevents cortisone-induced preadipocyte differentiation by depleting luminal NADPH of the endoplasmic reticulum ' (2008 ) 76 Biochem. Pharmacol. : 382 -390.

    • Search Google Scholar
  • Pereira, C. D., Azevedo, I., Monteiro, R., et al.: 11beta-hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus. Diabetes Obes. Metab., 2012, 14, 869–881.

    Monteiro R. , '11beta-hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus ' (2012 ) 14 Diabetes Obes. Metab. : 869 -881.

    • Search Google Scholar
  • Muñoz, R., Carvajal, C., Escalona, A., et al.: 11beta-hydroxysteroid dehydrogenase type 1 is overexpressed in subcutaneous adipose tissue of morbidly obese patients. Obes. Surg., 2009, 19, 764–770.

    Escalona A. , '11beta-hydroxysteroid dehydrogenase type 1 is overexpressed in subcutaneous adipose tissue of morbidly obese patients ' (2009 ) 19 Obes. Surg. : 764 -770.

    • Search Google Scholar
  • Swali, A., Walker, E. A., Lavery, G. G., et al.: 11beta-hydroxysteroid dehydrogenase type 1 regulates insulin and glucagon secretion in pancreatic islets. Diabetologia, 2008, 51, 2003–2011.

    Lavery G. G. , '11beta-hydroxysteroid dehydrogenase type 1 regulates insulin and glucagon secretion in pancreatic islets ' (2008 ) 51 Diabetologia : 2003 -2011.

    • Search Google Scholar
  • San Millán, J. L., Botella-Carretero, J. I., Alvarez-Blasco, F., et al.: A study of the hexose-6-phosphate dehydrogenase gene R453Q and 11beta-hydroxysteroid dehydrogenase type 1 gene 83557insA polymorphisms in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 2005, 90, 4157–4162.

    Alvarez-Blasco F. , 'A study of the hexose-6-phosphate dehydrogenase gene R453Q and 11beta-hydroxysteroid dehydrogenase type 1 gene 83557insA polymorphisms in the polycystic ovary syndrome ' (2005 ) 90 J. Clin. Endocrinol. Metab. : 4157 -4162.

    • Search Google Scholar
  • White, P. C.: Genotypes at 11beta-hydroxysteroid dehydrogenase type 11B1 and hexose-6-phosphate dehydrogenase loci are not risk factors for apparent cortisone reductase deficiency in a large population-based sample. J. Clin. Endocrinol. Metab., 2005, 90, 5880–5883.

    White P. C. , 'Genotypes at 11beta-hydroxysteroid dehydrogenase type 11B1 and hexose-6-phosphate dehydrogenase loci are not risk factors for apparent cortisone reductase deficiency in a large population-based sample ' (2005 ) 90 J. Clin. Endocrinol. Metab. : 5880 -5883.

    • Search Google Scholar
  • Lavery, G. G., Walker, E. A., Tiganescu, A., et al.: Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency. J. Clin. Endocrinol. Metab., 2008, 93, 3827–3832.

    Tiganescu A. , 'Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency ' (2008 ) 93 J. Clin. Endocrinol. Metab. : 3827 -3832.

    • Search Google Scholar
  • Lavery, G. G., Idkowiak, J., Sherlock, M., et al.: Novel H6PDH mutations in two girls with premature adrenarche: ‘Apparent’ and ‘true’ CRD can be differentiated by urinary steroid profiling. Eur. J. Endocrinol., 2012. november 6. DOI: 10.1530/EJE-12-0628 . [Epub ahead of print]

  • Lawson, A. J., Walker, E. A., Lavery, G. G., et al.: Cortisone-reductase deficiency associated with heterozygous mutations in 11beta-hydroxysteroid dehydrogenase type 1. Proc. Natl. Acad. Sci. USA, 2011, 108, 4111–4116.

    Lavery G. G. , 'Cortisone-reductase deficiency associated with heterozygous mutations in 11beta-hydroxysteroid dehydrogenase type 1 ' (2011 ) 108 Proc. Natl. Acad. Sci. USA : 4111 -4116.

    • Search Google Scholar
  • Caramelli, E., Strippoli, P., Di Giacomi, T., et al.: Lack of mutations of type 1 11beta-hydroxysteroid dehydrogenase gene in patients with abdominal obesity. Endocr. Res., 2001, 27, 47–61.

    Giacomi T. , 'Lack of mutations of type 1 11beta-hydroxysteroid dehydrogenase gene in patients with abdominal obesity ' (2001 ) 27 Endocr. Res. : 47 -61.

    • Search Google Scholar
  • De Quervain, D. J., Poirier, R., Wollmer, M. A., et al.: Glucocorticoid-related genetic susceptibility for Alzheimer’s disease. Hum. Mol. Genet., 2004, 13, 47–52.

    Wollmer M. A. , 'Glucocorticoid-related genetic susceptibility for Alzheimer’s disease ' (2004 ) 13 Hum. Mol. Genet. : 47 -52.

    • Search Google Scholar
  • Franks, P. W., Knowler, W. C., Nair, S., et al.: Interaction between an 11betaHSD1 gene variant and birth era modifies the risk of hypertension in Pima Indians. Hypertension, 2004, 44, 681–688.

    Nair S. , 'Interaction between an 11betaHSD1 gene variant and birth era modifies the risk of hypertension in Pima Indians ' (2004 ) 44 Hypertension : 681 -688.

    • Search Google Scholar
  • Gambineri, A., Vicennati, V., Genghini, S., et al.: Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 2006, 91, 2295–2302.

    Genghini S. , 'Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome ' (2006 ) 91 J. Clin. Endocrinol. Metab. : 2295 -2302.

    • Search Google Scholar
  • Nair, S., Lee, Y. H., Lindsay, R. S., et al.: 11beta-hydroxysteroid dehydrogenase type 1: genetic polymorphisms are associated with type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle. Diabetologia, 2004, 47, 1088–1095.

    Lindsay R. S. , '11beta-hydroxysteroid dehydrogenase type 1: genetic polymorphisms are associated with type 2 diabetes in Pima Indians independently of obesity and expression in adipocyte and muscle ' (2004 ) 47 Diabetologia : 1088 -1095.

    • Search Google Scholar
  • Dujic, T., Bego, T., Mlinar, B., et al.: Association between 11beta-hydroxysteroid dehydrogenase type 1 gene polymorphisms and metabolic syndrome in Bosnian population. Biochem. Med. (Zagreb), 2012, 22, 76–85.

    Mlinar B. , 'Association between 11beta-hydroxysteroid dehydrogenase type 1 gene polymorphisms and metabolic syndrome in Bosnian population ' (2012 ) 22 Biochem. Med. (Zagreb) : 76 -85.

    • Search Google Scholar
  • Robitaille, J., Brouillette, C., Houde, A., et al.: Molecular screening of the 11beta-HSD1 gene in men characterized by the metabolic syndrome. Obes. Res., 2004, 12, 1570–1575.

    Houde A. , 'Molecular screening of the 11beta-HSD1 gene in men characterized by the metabolic syndrome ' (2004 ) 12 Obes. Res. : 1570 -1575.

    • Search Google Scholar
  • Smit, P., Dekker, M. J., de Jong, F. J., et al.: Lack of association of the 11beta-hydroxysteroid dehydrogenase type 1 gene 83,557insA and hexose-6-phosphate dehydrogenase gene R453Q polymorphisms with body composition, adrenal androgen production, blood pressure, glucose metabolism, and dementia. J. Clin. Endocrinol. Metab., 2007, 92, 359–362.

    Jong F. J. , 'Lack of association of the 11beta-hydroxysteroid dehydrogenase type 1 gene 83,557insA and hexose-6-phosphate dehydrogenase gene R453Q polymorphisms with body composition, adrenal androgen production, blood pressure, glucose metabolism, and dementia ' (2007 ) 92 J. Clin. Endocrinol. Metab. : 359 -362.

    • Search Google Scholar
  • Moon, S. S., Lee, Y. S., Kim, J. G., et al.: Relationship of 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase gene polymorphisms with metabolic syndrome and type 2 diabetes. Endocr. J., 2011, 58, 949–959.

    Kim J. G. , 'Relationship of 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase gene polymorphisms with metabolic syndrome and type 2 diabetes ' (2011 ) 58 Endocr. J. : 949 -959.

    • Search Google Scholar
  • Draper, N., Powell, B. L., Franks, S., et al.: Variants implicated in cortisone reductase deficiency do not contribute to susceptibility to common forms of polycystic ovary syndrome. Clin. Endocrinol. (Oxf.), 2006, 65, 64–70.

    Franks S. , 'Variants implicated in cortisone reductase deficiency do not contribute to susceptibility to common forms of polycystic ovary syndrome ' (2006 ) 65 Clin. Endocrinol. (Oxf.) : 64 -70.

    • Search Google Scholar
  • Miyamoto, Y., Morisaki, H., Yamanaka, I., et al.: Association study of 11beta-hydroxysteroid dehydrogenase type 1 gene polymorphisms and metabolic syndrome in urban Japanese cohort. Diabetes Res. Clin. Pract., 2009, 85, 132–138.

    Yamanaka I. , 'Association study of 11beta-hydroxysteroid dehydrogenase type 1 gene polymorphisms and metabolic syndrome in urban Japanese cohort ' (2009 ) 85 Diabetes Res. Clin. Pract. : 132 -138.

    • Search Google Scholar
  • Olza, J., Gil-Campos, M., Leis, R., et al.: A gene variant of 11beta-hydroxysteroid dehydrogenase type 1 is associated with obesity in children. Int. J. Obes. (Lond.), 2012, 36, 1558–1563.

    Leis R. , 'A gene variant of 11beta-hydroxysteroid dehydrogenase type 1 is associated with obesity in children ' (2012 ) 36 Int. J. Obes. (Lond.) : 1558 -1563.

    • Search Google Scholar
  • Szappanos, A., Patocs, A., Gergics, P., et al.: The 83,557insA variant of the gene coding 11beta-hydroxysteroid dehydrogenase type 1 enzyme associates with serum osteocalcin in patients with endogenous Cushing’s syndrome. J. Steroid Biochem. Mol. Biol., 2011, 123, 79–84.

    Gergics P. , 'The 83,557insA variant of the gene coding 11beta-hydroxysteroid dehydrogenase type 1 enzyme associates with serum osteocalcin in patients with endogenous Cushing’s syndrome ' (2011 ) 123 J. Steroid Biochem. Mol. Biol. : 79 -84.

    • Search Google Scholar
  • Feigelson, H. S., Teras, L. R., Diver, W. R., et al.: Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II. Breast Cancer Res., 2008, 10, R57. DOI: 10.1186/bcr2114 . Epub 2008 Jul 8

    Diver W. R. , 'Genetic variation in candidate obesity genes ADRB2, ADRB3, GHRL, HSD11B1, IRS1, IRS2, and SHC1 and risk for breast cancer in the Cancer Prevention Study II ' (2008 ) 10 Breast Cancer Res. : R57 -.

    • Search Google Scholar
  • Hwang, J. Y., Lee, S. H., Kim, G. S., et al.: HSD11B1 polymorphisms predicted bone mineral density and fracture risk in postmenopausal women without a clinically apparent hypercortisolemia. Bone, 2009, 45, 1098–1103.

    Kim G. S. , 'HSD11B1 polymorphisms predicted bone mineral density and fracture risk in postmenopausal women without a clinically apparent hypercortisolemia ' (2009 ) 45 Bone : 1098 -1103.

    • Search Google Scholar
  • Rebhan, M., Chalifa-Caspi, V., Prilusky, J., et al.: GeneCards: integrating information about genes, proteins and diseases. Trends Genet., 1997, 13, 163.

    Prilusky J. , 'GeneCards: integrating information about genes, proteins and diseases ' (1997 ) 13 Trends Genet. : 163 -.

    • Search Google Scholar
  • Feldman, K., Szappanos, A., Butz, H., et al.: The rs4844880 polymorphism in the promoter region of the HSD11B1 gene associates with bone mineral density in healthy and postmenopausal osteoporotic women. Steroids, 2012, 77, 1345–1351.

    Butz H. , 'The rs4844880 polymorphism in the promoter region of the HSD11B1 gene associates with bone mineral density in healthy and postmenopausal osteoporotic women ' (2012 ) 77 Steroids : 1345 -1351.

    • Search Google Scholar
  • Rahman, T. J., Mayosi, B. M., Hall, D., et al.: Common variation at the 11-beta hydroxysteroid dehydrogenase type 1 gene is associated with left ventricular mass. Circ. Cardiovasc. Genet., 2011, 4, 156–162.

    Hall D. , 'Common variation at the 11-beta hydroxysteroid dehydrogenase type 1 gene is associated with left ventricular mass ' (2011 ) 4 Circ. Cardiovasc. Genet. : 156 -162.

    • Search Google Scholar
  • Gambineri, A., Tomassoni, F., Munarini, A., et al.: A combination of polymorphisms in HSD11B1 associates with in vivo 11{beta}-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome. Eur. J. Endocrinol., 2011, 165, 283–292.

    Munarini A. , 'A combination of polymorphisms in HSD11B1 associates with in vivo 11{beta}-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome ' (2011 ) 165 Eur. J. Endocrinol. : 283 -292.

    • Search Google Scholar
  • Courtney, R., Stewart, P. M., Toh, M., et al.: Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor. J. Clin. Endocrinol. Metab., 2008, 93, 550–556.

    Toh M. , 'Modulation of 11beta-hydroxysteroid dehydrogenase (11betaHSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11betaHSD1 inhibitor ' (2008 ) 93 J. Clin. Endocrinol. Metab. : 550 -556.

    • Search Google Scholar
  • Sundbom, M., Kaiser, C., Björkstrand, E., et al.: Inhibition of 11betaHSD1 with the S-phenylethylaminothiazolone BVT116429 increases adiponectin concentrations and improves glucose homeostasis in diabetic KKAy mice. BMC Pharmacol., 2008, 8, 3.

    Björkstrand E. , 'Inhibition of 11betaHSD1 with the S-phenylethylaminothiazolone BVT116429 increases adiponectin concentrations and improves glucose homeostasis in diabetic KKAy mice ' (2008 ) 8 BMC Pharmacol. : 3 -.

    • Search Google Scholar
  • Barf, T., Vallgårda, J., Emond, R., et al.: Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1. J. Med. Chem., 2002, 45, 3813–3815.

    Emond R. , 'Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1 ' (2002 ) 45 J. Med. Chem. : 3813 -3815.

    • Search Google Scholar
  • Bhat, B. G., Younis, H., Herrera, J., et al.: Antisense inhibition of 11betahydroxysteroid dehydrogenase type 1 improves diabetes in a novel cortisone-induced diabetic KK mouse model. Biochem. Biophys. Res. Commun., 2008, 365, 740–745.

    Herrera J. , 'Antisense inhibition of 11betahydroxysteroid dehydrogenase type 1 improves diabetes in a novel cortisone-induced diabetic KK mouse model ' (2008 ) 365 Biochem. Biophys. Res. Commun. : 740 -745.

    • Search Google Scholar
  • Blum, A., Favia, A. D., Maser, E.: 11beta-hydroxysteroid dehydrogenase type 1 inhibitors with oleanan and ursan scaffolds. Mol. Cell. Endocrinol., 2009, 301, 132–136.

    Maser E. , '11beta-hydroxysteroid dehydrogenase type 1 inhibitors with oleanan and ursan scaffolds ' (2009 ) 301 Mol. Cell. Endocrinol. : 132 -136.

    • Search Google Scholar
  • Su, X., Vicker, N., Trusselle, M., et al.: Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1. Mol. Cell. Endocrinol., 2009, 301, 169–173.

    Trusselle M. , 'Discovery of novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1 ' (2009 ) 301 Mol. Cell. Endocrinol. : 169 -173.

    • Search Google Scholar
  • Walker, B. R., Connacher, A. A., Lindsay, R. M., et al.: Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J. Clin. Endocrinol. Metab., 1995, 80, 3155–3159.

    Lindsay R. M. , 'Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation ' (1995 ) 80 J. Clin. Endocrinol. Metab. : 3155 -3159.

    • Search Google Scholar
  • Andrews, R. C., Rooyackers, O., Walker, B. R.: Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J. Clin. Endocrinol. Metab., 2003, 88, 285–291.

    Walker B. R. , 'Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes ' (2003 ) 88 J. Clin. Endocrinol. Metab. : 285 -291.

    • Search Google Scholar
  • Sandeep, T. C., Andrew, R., Homer, N. Z., et al.: Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone. Diabetes, 2005, 54, 872–879.

    Homer N. Z. , 'Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone ' (2005 ) 54 Diabetes : 872 -879.

    • Search Google Scholar
  • Tomlinson, J. W., Sherlock, M., Hughes, B., et al.: Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis. J. Clin. Endocrinol. Metab., 2007, 92, 857–864.

    Hughes B. , 'Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis ' (2007 ) 92 J. Clin. Endocrinol. Metab. : 857 -864.

    • Search Google Scholar
  • Rosenstock, J., Banarer, S., Fonseca, V. A., et al.: The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Diabetes Care, 2010, 33, 1516–1522.

    Fonseca V. A. , 'The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy ' (2010 ) 33 Diabetes Care : 1516 -1522.

    • Search Google Scholar
  • Feig, P. U., Shah, S., Hermanowski-Vosatka, A., et al.: Effects of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. Diabetes Obes. Metab., 2011, 13, 498–504.

    Hermanowski-Vosatka A. , 'Effects of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome ' (2011 ) 13 Diabetes Obes. Metab. : 498 -504.

    • Search Google Scholar
  • Shah, S., Hermanowski-Vosatka, A., Gibson, K., et al.: Efficacy and safety of the selective 11beta-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension. J. Am. Soc. Hypertens., 2011, 5, 166–176.

    Gibson K. , 'Efficacy and safety of the selective 11beta-HSD-1 inhibitors MK-0736 and MK-0916 in overweight and obese patients with hypertension ' (2011 ) 5 J. Am. Soc. Hypertens. : 166 -176.

    • Search Google Scholar